➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: August 15, 2020

DrugPatentWatch Database Preview

EPIPEN E Z PEN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Epipen E Z Pen, and when can generic versions of Epipen E Z Pen launch?

Epipen E Z Pen is a drug marketed by Mylan Speciality Lp and is included in one NDA.

The generic ingredient in EPIPEN E Z PEN is epinephrine. There are twenty-one drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

US ANDA Litigation and Generic Entry Outlook for Epipen E Z Pen

A generic version of EPIPEN E Z PEN was approved as epinephrine by BELCHER on July 29th, 2014.

  Start Trial

Drug patent expirations by year for EPIPEN E Z PEN
Recent Clinical Trials for EPIPEN E Z PEN

Identify potential brand extensions & 505(b)(2) entrants

Apimeds, Inc.Phase 3
University of North Carolina, Chapel HillPhase 1/Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)Phase 4

See all EPIPEN E Z PEN clinical trials

Paragraph IV (Patent) Challenges for EPIPEN E Z PEN
Tradename Dosage Ingredient NDA Submissiondate
EPIPEN E Z PEN INJECTABLE;INTRAMUSCULAR epinephrine 019430 2009-07-20
EPI E Z PEN JR INJECTABLE;INTRAMUSCULAR epinephrine 019430 2009-07-20

US Patents and Regulatory Information for EPIPEN E Z PEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Speciality Lp EPIPEN E Z PEN epinephrine INJECTABLE;INTRAMUSCULAR 019430-003 Aug 3, 1995 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.